PLAQUENIL MACULOPATHY
Hydroxychloroquine, commonly known by the trade name Plaquenil, is an important medication used in the management of a variety of autoimmune and inflammatory conditions, including rheumatoid arthritis, systemic lupus erythematosus and other connective tissue disorders(1). For many patients, hydroxychloroquine provides substantial benefits in disease control, symptom reduction and long-term health outcomes. Like all medications, however, long-term use may be associated with potential side effects, including rare effects upon the retina known as hydroxychloroquine retinopathy or Plaquenil maculopathy(2).
Although hydroxychloroquine retinopathy is uncommon, it is of particular importance because retinal damage may be irreversible once established(2,3). The condition affects the macula, the specialised central region of the retina responsible for detailed vision required for reading, driving, recognising faces and many occupational tasks. Fortunately, modern retinal imaging technologies are capable of detecting subtle retinal changes long before significant visual symptoms develop, allowing appropriate management decisions to be made at the earliest possible stage.
-
The retina contains highly specialised photoreceptor cells and supporting tissues that convert light into visual information for the brain. In susceptible individuals, prolonged exposure to hydroxychloroquine may result in toxic effects upon these retinal structures, particularly within the macular region. The risk of retinal toxicity is influenced by several factors, including daily dosage, duration of treatment, cumulative medication exposure, kidney function and the presence of certain pre-existing retinal conditions(2,4).
One of the challenges associated with hydroxychloroquine retinopathy is that patients often experience no symptoms during the earliest stages of disease. Vision may remain completely normal despite the presence of subtle retinal changes detectable on specialised testing. As toxicity progresses, however, patients may develop difficulties with reading, reduced visual sensitivity, blind spots near central vision, impaired colour perception or distortion of visual detail(2,3). Because established retinal damage may continue to progress even after cessation of the medication, early detection remains critically important.
Importantly, the possibility of retinal toxicity should not discourage patients from taking hydroxychloroquine when it has been prescribed appropriately. For many individuals, the systemic health benefits of treatment substantially outweigh the relatively low risk of ocular complications. Rather than avoiding treatment, the focus should be upon appropriate monitoring and early detection of any retinal changes that may occur during the course of therapy.
Current clinical guidelines recommend a baseline ocular assessment shortly after commencing hydroxychloroquine therapy, followed by regular screening examinations during ongoing treatment(2,5). The frequency of monitoring may vary depending upon individual risk factors, medication dosage and duration of use. For many patients, annual examinations form an important component of long-term management.
At Onèj Optometry, hydroxychloroquine screening involves a detailed assessment of retinal health using technologies specifically designed to detect the earliest signs of retinal toxicity. Optical coherence tomography (OCT) allows highly detailed cross-sectional imaging of the macula, enabling microscopic structural changes to be identified before noticeable vision loss occurs. Central visual field testing evaluates retinal function and may detect subtle changes in visual sensitivity associated with early toxicity. Together, these investigations provide complementary information regarding both the structure and function of the macula.
Because hydroxychloroquine retinopathy may develop gradually and without symptoms, repeated examinations over time are often required to accurately assess retinal stability. Careful comparison of current and previous results enables subtle changes to be identified with greater confidence and assists in determining whether further investigation or communication with the prescribing healthcare practitioner may be warranted.
At Onèj Optometry, we understand the importance of collaborative care. We work closely with rheumatologists, dermatologists, general practitioners and other healthcare providers involved in the management of patients taking hydroxychloroquine. Through comprehensive retinal assessment, advanced imaging and clear communication of findings, we aim to support both ocular health and broader medical management.
If you are currently taking Plaquenil or hydroxychloroquine, regular retinal monitoring forms an important part of protecting your long-term vision. Comprehensive examination with macular OCT and central visual field assessment can provide valuable information regarding retinal health and help ensure that any changes are identified at the earliest possible opportunity. Through ongoing monitoring and evidence-based care, it is often possible to detect retinal toxicity before meaningful visual impairment occurs, allowing informed decisions regarding future management.